Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 6/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.56 |
| ▸ | PYGL | P06737 | 2/20 | 0.53 |
| ▸ | PYGM | P11217 | 1/20 | 0.53 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607516 | 1.00 | ALOX15 (0.56) | ALOX15HRH4PYGLPYGMSMYD3 | |
| SCHEMBL3608594 | 1.00 | ALOX15 (0.56) | ALOX15HRH4PYGLPYGMSMYD3 | |
| SCHEMBL3608944 | 0.91 | SMYD3 (0.65) | HRH4PYGLPYGMSMYD3HRH3 | |
| SCHEMBL3608941 | 0.91 | SMYD3 (0.65) | HRH4PYGLPYGMSMYD3HRH3 | |
| SCHEMBL3610770 | 0.86 | DRD4 (0.57) | HRH4PYGLPYGMUSP30ROCK2 | |
| SCHEMBL3610774 | 0.86 | DRD4 (0.57) | HRH4PYGLPYGMUSP30ROCK2 | |
| SCHEMBL3602232 | 0.84 | ROCK2 (0.50) | HRH4PYGLSMYD3USP30ROCK2 | |
| SCHEMBL3602235 | 0.84 | ROCK2 (0.50) | HRH4PYGLSMYD3USP30ROCK2 | |
| SCHEMBL3599303 | 0.82 | RHEB (0.50) | HRH4PYGLPYGMSMYD3ROCK2 | |
| SCHEMBL3599300 | 0.82 | RHEB (0.50) | HRH4PYGLPYGMSMYD3ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
| WO-2009158375-A1 | AZA-CYLIC INDOLE- 2 -CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | ALOX15 1315/4885HRH4 396/4885PYGL 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.